Dose finding study of mosapride in functional dyspepsia: A placebo-controlled, randomized study

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 5, 2002, Pages 959-967

  Hallerback B I ^a,h   Bommelaer, G ^b   Bredberg, E ^c   Campbell, M ^d   Hellblom, M ^e   Lauritsen, K ^f   Wienbeck, M ^g   Holmgren, L L ^c  

^a Surgical Department   (Sweden)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^c ASTRAZENECA R AND D   (Sweden)

^d Southbank Surgery   (United Kingdom)

^e Central Hospital   (Sweden)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

^g KLINIKUM AUGSBURG   (Germany)

^h Department of Orthopaedics   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MOSAPRIDE CITRATE; PROKINETIC AGENT; SEROTONIN 4 AGONIST;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DYSPEPSIA; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TREATMENT OUTCOME;

ADULT; BENZAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSPEPSIA; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; TREATMENT OUTCOME;

EID: 0036234667     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01236.x     Document Type: Article

References (52)

1. Functional dyspepsia: A classification with guidelines for diagnosis and management
2. Dyspepsia in England and Scotland
3. Functional gastroduodenal disorders
4. Non-ulcer dyspepsia: Potential causes and pathophysiology
5. Upper gut motility and perception in functional dyspepsia. Review in depth. Functional dyspepsia
6. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia
7. AGA Technical review. Evaluation of dyspepsia
8. Gut sensitivity in functional dyspepsia. Review in depth. Functional dyspepsia
9. Organic causes of dyspepsia, and discriminating functional from organic dyspepsia
10. Principles of applied neurogastroenterology: Physiology/motility-sensation
11. Psychosocial factors in functional dyspepsia. Review in depth. Functional dyspepsia
12. Functional dyspepsia: Is gastric acid and/or Helicobacter pylori infection involved in the aetiology? Review in depth. Functional dyspepsia
13. Effect of mental stress and cisapride on autonomic nerve functions in functional dyspepsia
14. Functional gastrointestinal disorders: Psychological, social and somatic features
15. Evidence for hypomotility in non-ulcer dyspepsia: A prospective multifactorial study
16. Role of impaired gastric accommodation to a meal in functional dyspepsia
17. Imaging studies in dyspepsia
18. Timing of post-prandial dyspeptic symptoms and transpyloric passage of gastric contents
19. Visceral perception in health and functional dyspepsia. Crossover study of gastric distension with placebo and domperidone
20. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia
21. A double blind, randomised, placebo-controlled trial of cisapride in Saudi Arabs with functional dyspepsia
22. Cisapride treatment of patients with non-ulcer dyspepsia and erosive pre-pyloric changes. A double blind, placebo controlled trial
23. Clinical trial on the effect of domperidone on non-ulcer dyspepsia
24. Drug treatment of functional dyspepsia
25. Efficacy of cisapride therapy in functional dyspepsia
26. A double blind randomised study of cisapride in the treatment of non-ulcer dyspepsia
27. Effect of cisapride on functional dyspepsia in patients with and without histological gastritis: A double-blind placebo-controlled trial
28. Meta analysis of antisecretory and gastrokinetic compounds in functional dyspepsia
29. Cisapride in functional dyspepsia in general practice. A placebo-controlled, randomized, double blind study
30. Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia
31. Prokinetic effect of AS-4370 on gastric emptying in healthy adults
32. Novel benzamides as selective and potent gastric prokinetic agents, 2. Synthesis and structure-activity relationships of 4-amina-5-chlor-2-ethoxy-N-((4-(4-fluorobenzyl)-2-morpholinyl)methyl) benzamide citrate (AS-4370) and related compounds
33. Effect of AS-4370 on gastric motility in patients with diabetic autonomic neuropathy
34. Pharmacological studies on mosapride citrate (AS-4370), a gastroprokinetic agent - Comparison with cisapride and metoclopramide
35. AS-4370, a new gastrokinetic agent, is a partial 5-hydroxy-tryptamine 4 receptor agonist in the gut
36. Dose finding study of AS-4370 in patients with chronic gastritis
37. Validation of seven graded diary cards for severity of dyspeptic symptoms in patients with non-ulcer dyspepsia
38. Functional dyspepsia. Current treatment and recommendations
39. Drug treatment of functional dyspepsia: A systematic analysis of trial methodology with recommendations for design of future trials
40. Design of treatment trials for functional gastrointestinal disorders
41. Functional bowel disorders and functional abdominal pain
42. Chronic dyspepsia: Double blind treatment with domperidone (R33 812) or a placebo. A multicentre therapeutic evaluation
43. Domperidone in the treatment of functional dyspepsia in patients with delayed gastric emptying
44. Oral domperidone in chronic postprandial dyspepsia
45. Efficacy of cisapride in patients with non-ulcer dyspepsia
46. Cisapride in chronic dyspepsia. Result of a double blind, placebo-controlled trial
47. Cisapride in non-ulcer dyspepsia
48. Efficacy of cisapride in the treatment of epigastric pain and concomitant symptoms in non-ulcer dyspepsia
49. Relief of epigastric pain in nonulcer dyspepsia: Controlled trial of the promotility drug cisapride
50. Non-ulcer dyspepsia: Effect of the gastrointestinal prokinetic drug cisapride
51. Functional gastroduodenal disorders
52. Optimal design of treatment trials